-

Bruker Introduces Enhanced 3D Holographic Stimulation for Optogenetics on its Ultima 2Pplus Multiphoton Microscope

New NeuraLight 3D Ultra Module Expands Neuroscience Research Capabilities

MADISON, Wis.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the release of the NeuraLight 3D Ultra module to support advanced neuroscience and optogenetics research applications on Bruker’s Ultima multiphoton microscopes. NeuraLight 3D Ultra provides revolutionary 3D holographic photostimulation, specifically optimized for functional and large-scale studies of neural networks and brain computation. Building upon Bruker’s proprietary spatial light modulator (SLM) technology, the NeuraLight 3D Ultra module utilizes a new, larger liquid crystal chip that unlocks access to a larger field of view, improved targeting precision, and a market-leading speed of 600 hologram frames per second. Paired with the imaging capabilities of the Ultima 2Pplus microscope, it uniquely allows researchers to study mechanisms of behavior, perception, and disease at a larger scale and on a time scale that is reflective of the underlying biology.

“The system is performing very well in our laboratory, and we’re excited about the NeuraLight 3D Ultra’s speed, field of view, and resolution, which will enable us to perform all-optical interrogation experiments with greater fidelity and precision,” said Dr. Adam Packer, Wellcome Trust Sir Henry Dale Fellow at the University of Oxford. “The new format SLM and associated optical relays offer a better tradeoff between field of view and resolution that will be advantageous to addressing larger numbers of cells with improved accuracy. Additionally, the very fast update speed of the system will make it possible to activate sequences of cells at a high rate.”

“We are pleased to continue to develop innovative instrumentation in close collaboration with leaders in neuroscience research,” added Xiaomei Li, Ph.D., Vice President and General Manager for Bruker’s Fluorescence Microscopy Business. “With its largest in-class field of view in fast resonant mode, the Ultima 2Pplus microscope equipped with NeuraLight 3D Ultra is an optimized solution for all-optical interrogations of the brain.”

About NeuraLight 3D Ultra

The NeuraLight 3D Ultra is a module that strengthens and diversifies the functionality of Bruker’s Ultima multiphoton microscopes. These pioneering imaging systems have a proven track record of facilitating complex research in neuroscience and were first to enable simultaneous imaging and photostimulation of biological samples. NeuraLight 3D Ultra easily couples to one of the optical ports of the Ultima microscope to allow for independent imaging and simultaneous multicellular photostimulation. Comprehensive software enables user-friendly selection of targets in three dimensions with well-defined timing. The NeuraLight 3D Ultra module is available as an option for all new Ultima 2Pplus multiphoton microscopes and as an upgrade for selected models of microscopes produced since 2006. Ultima multiphoton systems equipped with NeuraLight 3D Ultra and paired with Bruker’s electrotunable lens option provide complete solutions for all-optical reading and writing of neuronal activity.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward
Senior Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Stephen Hopkins
Content Marketing Manager
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Justin Ward
Senior Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Stephen Hopkins
Content Marketing Manager
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit...

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus...
Back to Newsroom